Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,130 INR | -1.97% |
|
-1.21% | +58.56% |
Jun. 28 | Orchid Pharma Partners with Cipla to Launch Antibiotic Cefepime- Enmetazobactam in India | CI |
Jun. 06 | Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+58.56% | 686M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- ORCHPHARMA Stock
- News Orchid Pharma Limited
- CARE Upgrades Rating on Orchid Pharma's Long-term Bank Financing to BBB; Outlook Stable